|
ES2384160T3
(es)
|
1999-01-13 |
2012-07-02 |
Bayer Healthcare Llc |
Difenil ureas sustituidas con omega-carboxi arilo como agentes inhibidores de la cinasa p38
|
|
US8124630B2
(en)
|
1999-01-13 |
2012-02-28 |
Bayer Healthcare Llc |
ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
HU230302B1
(hu)
|
2000-10-20 |
2015-12-28 |
Eisai R&D Management Co., Ltd. |
Nitrogéntartalmú aromás származékok és ezeket tartalmazó gyógyászati készítmények
|
|
PT2305255E
(pt)
†
|
2001-12-03 |
2012-09-04 |
Bayer Healthcare Llc |
Compostos de arilureia em combinação com outros agentes citostáticos ou citotóxicos para tratamento de cancros humanos
|
|
EP1478358B1
(en)
|
2002-02-11 |
2013-07-03 |
Bayer HealthCare LLC |
Sorafenib tosylate for the treatment of diseases characterized by abnormal angiogenesis
|
|
EA007987B1
(ru)
|
2002-03-29 |
2007-02-27 |
Чирон Корпорейшн |
Замещённые бензазолы и их применение в качестве ингибиторов киназы raf
|
|
US8299108B2
(en)
|
2002-03-29 |
2012-10-30 |
Novartis Ag |
Substituted benzazoles and methods of their use as inhibitors of raf kinase
|
|
AU2003246972A1
(en)
|
2002-08-06 |
2004-02-23 |
Astrazeneca Ab |
Condensed pyridines and pyrimidines with tie2 (tek) activity
|
|
KR100732440B1
(ko)
*
|
2002-08-30 |
2007-06-27 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
질소 함유 방향환 유도체
|
|
US7365209B2
(en)
|
2003-02-11 |
2008-04-29 |
Pharmacopeia, Inc. |
Nitrogen heterocycle biaryls for osteoporosis and other diseases
|
|
US7531553B2
(en)
|
2003-03-21 |
2009-05-12 |
Amgen Inc. |
Heterocyclic compounds and methods of use
|
|
MXPA05010496A
(es)
*
|
2003-03-28 |
2005-11-16 |
Pharmacia & Upjohn Co Llc |
Moduladores alostericos positivos del receptor de acetilcolina nicotinico.
|
|
US7893096B2
(en)
|
2003-03-28 |
2011-02-22 |
Novartis Vaccines And Diagnostics, Inc. |
Use of small molecule compounds for immunopotentiation
|
|
DK1626714T3
(da)
|
2003-05-20 |
2007-10-15 |
Bayer Pharmaceuticals Corp |
Dirarylurinstoffer mod sygdomme medieret af PDGFR
|
|
US6887798B2
(en)
|
2003-05-30 |
2005-05-03 |
International Business Machines Corporation |
STI stress modification by nitrogen plasma treatment for improving performance in small width devices
|
|
EP1653951B1
(en)
*
|
2003-07-11 |
2011-12-28 |
Merck Patent GmbH |
Benzimidazole derivatives as raf kinase inhibitors
|
|
EA010485B1
(ru)
|
2003-07-23 |
2008-10-30 |
Байер Фамэсьютиклс Копэрейшн |
Производное n,n'-дифенилмочевины, фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с его использованием (варианты)
|
|
DE10334663A1
(de)
*
|
2003-07-30 |
2005-03-10 |
Merck Patent Gmbh |
Harnstoffderivate
|
|
DE10337942A1
(de)
*
|
2003-08-18 |
2005-03-17 |
Merck Patent Gmbh |
Aminobenzimidazolderivate
|
|
DE10342503A1
(de)
*
|
2003-09-12 |
2005-04-14 |
Merck Patent Gmbh |
Benzyl-Benzimidazolylderivate
|
|
DE10344223A1
(de)
*
|
2003-09-24 |
2005-04-21 |
Merck Patent Gmbh |
1,3-Benzoxazolylderivate als Kinase-Inhibitoren
|
|
KR20060118472A
(ko)
|
2003-10-16 |
2006-11-23 |
카이론 코포레이션 |
치환 벤자졸 및 ｒａｆ 키나아제의 저해제로서 그것의 사용
|
|
DE10349587A1
(de)
|
2003-10-24 |
2005-05-25 |
Merck Patent Gmbh |
Benzimidazolylderivate
|
|
CN101337930B
(zh)
|
2003-11-11 |
2010-09-08 |
卫材R&D管理有限公司 |
脲衍生物的制备方法
|
|
DE10352979A1
(de)
*
|
2003-11-13 |
2005-06-09 |
Merck Patent Gmbh |
Pyridopyrimidinone
|
|
US20050267182A1
(en)
*
|
2003-11-13 |
2005-12-01 |
Ambit Biosciences Corporation |
Urea derivatives as FLT-3 modulators
|
|
TW200530236A
(en)
|
2004-02-23 |
2005-09-16 |
Chugai Pharmaceutical Co Ltd |
Heteroaryl phenylurea
|
|
EP1718637A2
(en)
*
|
2004-02-26 |
2006-11-08 |
MERCK PATENT GmbH |
Benzimidazolyl derivatives as kinase inhibitors
|
|
US7459562B2
(en)
|
2004-04-23 |
2008-12-02 |
Bristol-Myers Squibb Company |
Monocyclic heterocycles as kinase inhibitors
|
|
TW200538453A
(en)
|
2004-04-26 |
2005-12-01 |
Bristol Myers Squibb Co |
Bicyclic heterocycles as kinase inhibitors
|
|
EP1751139B1
(en)
|
2004-04-30 |
2011-07-27 |
Bayer HealthCare LLC |
Substituted pyrazolyl urea derivatives useful in the treatment of cancer
|
|
US7439246B2
(en)
|
2004-06-28 |
2008-10-21 |
Bristol-Myers Squibb Company |
Fused heterocyclic kinase inhibitors
|
|
US7432373B2
(en)
|
2004-06-28 |
2008-10-07 |
Bristol-Meyers Squibb Company |
Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
|
|
US20050288290A1
(en)
|
2004-06-28 |
2005-12-29 |
Borzilleri Robert M |
Fused heterocyclic kinase inhibitors
|
|
US20090181092A1
(en)
*
|
2004-07-16 |
2009-07-16 |
Spinal Restoration, Inc. |
Methods for Treating Joints and Discs with a Carrier Matrix and Cells
|
|
EP1797881B1
(en)
|
2004-09-17 |
2009-04-15 |
Eisai R&D Management Co., Ltd. |
Medicinal composition with improved stability and reduced gelation properties
|
|
JP4789180B2
(ja)
*
|
2004-09-28 |
2011-10-12 |
第一三共株式会社 |
６−置換−１−メチル−１−ｈ−ベンズイミダゾール誘導体の製造方法及びその製造中間体
|
|
CN101068770B
(zh)
*
|
2004-09-28 |
2012-01-04 |
三共株式会社 |
制备6-取代的-1-甲基-1-h-苯并咪唑衍生物的方法及其合成中间体
|
|
WO2006040056A1
(en)
*
|
2004-10-13 |
2006-04-20 |
Merck Patent Gmbh |
Heterocyclic substituted bisarylurea derivatives as kinase inhibitors
|
|
WO2006040039A1
(de)
*
|
2004-10-13 |
2006-04-20 |
Merck Patent Gmbh |
Als kinaseinhibitoren geeignete derivate des n, n ´ -diphenylharnstoffs
|
|
GB0423554D0
(en)
|
2004-10-22 |
2004-11-24 |
Cancer Rec Tech Ltd |
Therapeutic compounds
|
|
DE102004054216A1
(de)
|
2004-11-10 |
2006-05-11 |
Merck Patent Gmbh |
Substituierte 4-Amino-pyridopyrimidinone
|
|
EP1674466A1
(en)
*
|
2004-12-27 |
2006-06-28 |
4Sc Ag |
2,5- and 2,6-disubstituted benzazole analogues useful as protein kinase inhibitors
|
|
US7576090B2
(en)
|
2004-12-27 |
2009-08-18 |
4Sc Ag |
Benzazole analogues and uses thereof
|
|
WO2007015578A1
(ja)
|
2005-08-02 |
2007-02-08 |
Eisai R & D Management Co., Ltd. |
血管新生阻害物質の効果を検定する方法
|
|
US7202513B1
(en)
|
2005-09-29 |
2007-04-10 |
International Business Machines Corporation |
Stress engineering using dual pad nitride with selective SOI device architecture
|
|
EP1940841B9
(fr)
|
2005-10-07 |
2017-04-19 |
Guerbet |
Composes comprenant une partie de reconnaissance d'une cible biologique, couplee a une partie de signal capable de complexer le gallium
|
|
US8986650B2
(en)
|
2005-10-07 |
2015-03-24 |
Guerbet |
Complex folate-NOTA-Ga68
|
|
JP5328640B2
(ja)
*
|
2006-04-19 |
2013-10-30 |
ノバルティス アーゲー |
６−ｏ−置換ベンゾオキサゾールおよびベンゾチアゾール化合物ならびにｃｓｆ−１ｒシグナル伝達を阻害する方法
|
|
WO2007125330A1
(en)
|
2006-04-26 |
2007-11-08 |
Cancer Research Technology Limited |
Imidazo[4, 5-b]pyridin-2-one and oxazolo[4, 5-b]pyridin-2-one compounds and analogs thereof as cancer therapeutic compounds
|
|
EA200802058A1
(ru)
|
2006-05-09 |
2009-06-30 |
Пфайзер Продактс Инк. |
Производные циклоалкиламинокислот и их фармацевтические композиции
|
|
ES2556173T3
(es)
|
2006-05-18 |
2016-01-13 |
Eisai R&D Management Co., Ltd. |
Agente antitumoral para un cáncer de tiroides
|
|
CN101511793B
(zh)
|
2006-08-28 |
2011-08-03 |
卫材R&D管理有限公司 |
针对未分化型胃癌的抗肿瘤剂
|
|
JP2010504362A
(ja)
*
|
2006-09-25 |
2010-02-12 |
アレテ セラピューティクス， インコーポレイテッド |
可溶性エポキシドヒドロラーゼ阻害剤
|
|
WO2008039999A1
(en)
*
|
2006-09-28 |
2008-04-03 |
Arete Therapeutics, Inc. |
Soluble epoxide hydrolase inhibitors
|
|
KR101445892B1
(ko)
|
2007-01-29 |
2014-09-29 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
미분화형 위암 치료용 조성물
|
|
PE20090370A1
(es)
*
|
2007-06-05 |
2009-04-30 |
Takeda Pharmaceutical |
Derivados de heterociclo fusionado como inhibidores de quinasa
|
|
US8431608B2
(en)
|
2007-08-17 |
2013-04-30 |
Icagen Inc. |
Heterocycles as potassium channel modulators
|
|
US8058274B2
(en)
*
|
2007-08-17 |
2011-11-15 |
Icagen, Inc. |
Heterocycles as potassium channel modulators
|
|
WO2009025358A1
(ja)
|
2007-08-23 |
2009-02-26 |
Takeda Pharmaceutical Company Limited |
複素環化合物およびその用途
|
|
JP5350247B2
(ja)
*
|
2007-08-29 |
2013-11-27 |
武田薬品工業株式会社 |
複素環化合物およびその用途
|
|
CN101848895B
(zh)
|
2007-11-09 |
2013-10-23 |
卫材R&D管理有限公司 |
血管新生抑制物质和抗肿瘤性铂络合物的组合使用
|
|
EA019974B1
(ru)
|
2007-12-19 |
2014-07-30 |
Кансер Рисерч Текнолоджи Лимитед |
8-ЗАМЕЩЕННЫЕ ПИРИДО[2,3-b]ПИРАЗИНЫ И ИХ ПРИМЕНЕНИЕ
|
|
JPWO2009128520A1
(ja)
|
2008-04-18 |
2011-08-04 |
塩野義製薬株式会社 |
Ｐｉ３ｋ阻害活性を有する複素環化合物
|
|
GB0807609D0
(en)
*
|
2008-04-25 |
2008-06-04 |
Cancer Rec Tech Ltd |
Therapeutic compounds and their use
|
|
US8445509B2
(en)
|
2008-05-08 |
2013-05-21 |
Takeda Pharmaceutical Company Limited |
Fused heterocyclic derivatives and use thereof
|
|
EP2307456B1
(en)
|
2008-06-27 |
2014-10-15 |
Amgen Inc. |
Ang-2 inhibition to treat multiple sclerosis
|
|
JP5579619B2
(ja)
*
|
2008-12-01 |
2014-08-27 |
武田薬品工業株式会社 |
複素環化合物およびその用途
|
|
JO3101B1
(ar)
*
|
2008-12-02 |
2017-09-20 |
Takeda Pharmaceuticals Co |
مشتقات بنزوثيازول كعوامل مضادة للسرطان
|
|
FR2942227B1
(fr)
|
2009-02-13 |
2011-04-15 |
Guerbet Sa |
Utilisation de tampons pour la complexation de radionucleides
|
|
WO2010126922A1
(en)
*
|
2009-04-30 |
2010-11-04 |
Glaxosmithkline Llc |
Benzimidazolecarboxamides as inhibitors of fak
|
|
CN102906090B
(zh)
|
2010-02-01 |
2015-06-24 |
癌症研究技术有限公司 |
1-(5-叔丁基-2-苯基-2h-吡唑-3-基)-3-[2-氟-4-(1-甲基-2-氧代-2,3-二氢-1h-咪唑并[4,5-b]吡啶-7-基氧基)-苯基]-脲和相关化合物及它们在治疗中的应用
|
|
EA201290808A1
(ru)
|
2010-02-18 |
2013-03-29 |
ХАЙ ПОЙНТ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи |
Замещенные конденсированные производные имидазола, фармацевтические композиции и способы их применения
|
|
US8759535B2
(en)
|
2010-02-18 |
2014-06-24 |
High Point Pharmaceuticals, Llc |
Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
|
|
CA2802644C
(en)
|
2010-06-25 |
2017-02-21 |
Eisai R & D Management Co., Ltd. |
Antitumor agent using compounds having kinase inhibitory effect in combination
|
|
TW201217359A
(en)
|
2010-09-03 |
2012-05-01 |
Forma Therapeutics Inc |
Novel compounds and compositions for the inhibition of NAMPT
|
|
FR2968999B1
(fr)
|
2010-12-20 |
2013-01-04 |
Guerbet Sa |
Nanoemulsion de chelate pour irm
|
|
RU2580609C2
(ru)
|
2011-04-18 |
2016-04-10 |
Эйсай Ар Энд Ди Менеджмент Ко., Лтд. |
Противоопухолевое терапевтическое средство
|
|
EP3444363B1
(en)
|
2011-06-03 |
2020-11-25 |
Eisai R&D Management Co., Ltd. |
Biomarkers for prediciting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
|
|
FR2980364B1
(fr)
|
2011-09-26 |
2018-08-31 |
Guerbet |
Nanoemulsions et leur utilisation comme agents de contraste
|
|
AU2013364953A1
(en)
|
2012-12-21 |
2015-04-30 |
Eisai R&D Management Co., Ltd. |
Amorphous form of quinoline derivative, and method for producing same
|
|
FR3001154B1
(fr)
|
2013-01-23 |
2015-06-26 |
Guerbet Sa |
Magneto-emulsion vectorisee
|
|
US9242969B2
(en)
|
2013-03-14 |
2016-01-26 |
Novartis Ag |
Biaryl amide compounds as kinase inhibitors
|
|
WO2014185540A1
(en)
|
2013-05-14 |
2014-11-20 |
Eisai R&D Management Co., Ltd. |
Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
|
|
JP6557654B2
(ja)
*
|
2013-05-30 |
2019-08-07 |
カラ ファーマシューティカルズ インコーポレイテッド |
新規の化合物及びその使用
|
|
GB201320729D0
(en)
|
2013-11-25 |
2014-01-08 |
Cancer Rec Tech Ltd |
Therapeutic compounds and their use
|
|
GB201320732D0
(en)
|
2013-11-25 |
2014-01-08 |
Cancer Rec Tech Ltd |
Methods of chemical synthesis
|
|
KR102329681B1
(ko)
|
2014-08-28 |
2021-11-23 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
고순도의 퀴놀린 유도체 및 이를 제조하는 방법
|
|
UY36294A
(es)
|
2014-09-12 |
2016-04-29 |
Novartis Ag |
Compuestos y composiciones como inhibidores de quinasa
|
|
WO2016089648A1
(en)
|
2014-12-01 |
2016-06-09 |
Vtv Therapeutics Llc |
Bach 1 inhibitors in combination with nrf2 activators and pharmaceutical compositions thereof
|
|
KR20250024102A
(ko)
|
2015-02-25 |
2025-02-18 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
퀴놀린 유도체의 고미 억제 방법
|
|
AU2015384801B2
(en)
|
2015-03-04 |
2022-01-06 |
Eisai R&D Management Co., Ltd. |
Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
|
|
ES2886107T3
(es)
|
2015-06-16 |
2021-12-16 |
Prism Biolab Co Ltd |
Antineoplásico
|
|
SG11201801083UA
(en)
|
2015-08-20 |
2018-03-28 |
Eisai R&D Man Co Ltd |
Tumor therapeutic agent
|
|
EP3889139B1
(en)
|
2015-11-30 |
2025-03-19 |
The Children's Medical Center Corporation |
Compounds for treating proliferative diseases
|
|
KR102341660B1
(ko)
|
2016-09-19 |
2021-12-23 |
노파르티스 아게 |
Raf 억제제 및 erk 억제제를 포함하는 치료적 조합
|
|
US12303505B2
(en)
|
2017-02-08 |
2025-05-20 |
Eisai R&D Management Co., Ltd. |
Tumor-treating pharmaceutical composition
|
|
ES2952265T3
(es)
|
2017-05-02 |
2023-10-30 |
Novartis Ag |
Terapia combinada que comprende un inhibidor de Raf y trametinib
|
|
US20200197384A1
(en)
|
2017-05-16 |
2020-06-25 |
Eisai R&D Management Co., Ltd. |
Treatment of hepatocellular carcinoma
|
|
CN107954939B
(zh)
*
|
2017-12-07 |
2019-09-17 |
福建医科大学 |
一种微波辐射下n,n-二甲基氨基硫代甲酰氯衍生物催化合成苯并咪唑衍生物的方法
|
|
EP3876939A4
(en)
|
2018-11-07 |
2022-08-10 |
Dana-Farber Cancer Institute, Inc. |
Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
|
|
WO2020201773A1
(en)
*
|
2019-04-05 |
2020-10-08 |
Storm Therapeutics Ltd |
Mettl3 inhibitory compounds
|
|
EP3969449B1
(en)
|
2019-05-13 |
2025-02-12 |
Novartis AG |
New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer
|
|
BR112022022409A2
(pt)
|
2020-05-06 |
2023-02-07 |
Ajax Therapeutics Inc |
6-heteroarilóxi benzimidazóis e azabenzimidazóis como inibidores de jak2
|
|
US20230391753A1
(en)
*
|
2020-10-19 |
2023-12-07 |
Korea University Research And Business Foundation |
Thiobenzimidazole derivative or pharmaceutically acceptable salt thereof and use thereof
|
|
EP4267574B1
(en)
|
2020-12-23 |
2025-04-23 |
Ajax Therapeutics, Inc. |
6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
|
|
US11970494B2
(en)
|
2021-11-09 |
2024-04-30 |
Ajax Therapeutics, Inc. |
6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors
|
|
WO2023086320A1
(en)
|
2021-11-09 |
2023-05-19 |
Ajax Therapeutics, Inc. |
Forms and compositions of inhibitors of jak2
|
|
TW202346485A
(zh)
|
2022-03-28 |
2023-12-01 |
瑞士商杭斯曼高級材料公司 |
基於2-羥基萘-3-羧酸的分散偶氮染料
|
|
CN115724837B
(zh)
*
|
2022-10-26 |
2024-07-23 |
中国人民解放军海军军医大学 |
一种抑制程序性细胞坏死的苯并噻唑衍生物及其应用
|